Meningococcal vaccine groups A B C Y W-135 conjugate - GSK
Alternative Names: GSK-3536819A; GSK3536819; MenABCWY (1st Gen); Meningococcal ABCWY Vaccine; Penmenvy; rMenB + MenACWYLatest Information Update: 23 Apr 2025
At a glance
- Originator Novartis
- Developer GSK
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 16 Apr 2025 US Centers for Disease Control and Prevention’s (CDC) Advisory Committee gives positive recommendation for Meningococcal vaccine groups A B C Y W-135 conjugate
- 15 Feb 2025 Registered for Meningococcal group A infections (In adolescents, In children, Prevention, In adults) in USA (IM)
- 15 Feb 2025 Registered for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in USA (IM)